ES2670499T3 - Retinoides y uso de los mismos - Google Patents

Retinoides y uso de los mismos Download PDF

Info

Publication number
ES2670499T3
ES2670499T3 ES13831096.6T ES13831096T ES2670499T3 ES 2670499 T3 ES2670499 T3 ES 2670499T3 ES 13831096 T ES13831096 T ES 13831096T ES 2670499 T3 ES2670499 T3 ES 2670499T3
Authority
ES
Spain
Prior art keywords
substituted
composition
compound
use according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13831096.6T
Other languages
English (en)
Spanish (es)
Inventor
Wayne J. Brouillette
Donald D. Muccio
Venkatram Reddy Atigadda
John M. Ruppert
Susan M. Lobo Ruppert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Application granted granted Critical
Publication of ES2670499T3 publication Critical patent/ES2670499T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Birds (AREA)
ES13831096.6T 2012-08-24 2013-07-01 Retinoides y uso de los mismos Active ES2670499T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201213594177 2012-08-24
US13/594,177 US8475775B1 (en) 2012-08-24 2012-08-24 Retinoids and use thereof
PCT/US2013/048891 WO2014031242A1 (en) 2012-08-24 2013-07-01 Retinoids and use thereof

Publications (1)

Publication Number Publication Date
ES2670499T3 true ES2670499T3 (es) 2018-05-30

Family

ID=48671166

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13831096.6T Active ES2670499T3 (es) 2012-08-24 2013-07-01 Retinoides y uso de los mismos

Country Status (18)

Country Link
US (3) US8475775B1 (OSRAM)
EP (1) EP2887928B1 (OSRAM)
JP (1) JP6382817B2 (OSRAM)
KR (1) KR20150045450A (OSRAM)
CN (1) CN104540502A (OSRAM)
AU (1) AU2013306281B2 (OSRAM)
BR (1) BR112015003561A8 (OSRAM)
CA (1) CA2882330A1 (OSRAM)
CL (1) CL2015000434A1 (OSRAM)
CO (1) CO7350653A2 (OSRAM)
ES (1) ES2670499T3 (OSRAM)
HU (1) HUE037075T2 (OSRAM)
IL (1) IL236991B (OSRAM)
IN (1) IN2015DN01524A (OSRAM)
MX (1) MX366050B (OSRAM)
NZ (1) NZ704496A (OSRAM)
RU (1) RU2687285C2 (OSRAM)
WO (1) WO2014031242A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328040B2 (en) 2014-01-17 2019-06-25 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic methods
WO2015130973A1 (en) 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140979A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US11696897B2 (en) * 2019-10-02 2023-07-11 Georg-August-Universitat Gottingen Stiftung Offentlichen Rechts, Universitatsmedizin Method for the treatment of diseases associated with sulfatase deficiencies
JP2022056688A (ja) * 2020-09-30 2022-04-11 キオクシア株式会社 半導体装置
CN113207799B (zh) * 2021-03-19 2022-03-15 中山大学 一种二型糖尿病小鼠快速心衰模型的构建方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094783A (en) * 1990-06-29 1992-03-10 Uab Research Foundation Retinoid compounds
DE69942505D1 (de) * 1998-04-06 2010-07-29 Uab Research Foundation Neuartige retinoide und deren verwendung
JP4699347B2 (ja) * 2003-01-17 2011-06-08 ウィスコンシン・アルムニ・リサーチ・ファウンデーション 改質されたレチノイド化合物及びその使用
CA2578267C (en) 2004-08-24 2014-04-15 The Uab Research Foundation Methods for making retinoids and uses thereof
US20100247461A1 (en) * 2009-01-20 2010-09-30 Signum Biosciences, Inc. Anti-inflammatory complexes
WO2011141822A2 (en) * 2010-05-11 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for induction, predictive diagnosis, and treatment of affective behaviors by modulation of ppar and rxr receptors

Also Published As

Publication number Publication date
HUE037075T2 (hu) 2018-08-28
CA2882330A1 (en) 2014-02-27
MX366050B (es) 2019-06-26
US20150202174A1 (en) 2015-07-23
AU2013306281A1 (en) 2015-02-26
EP2887928B1 (en) 2018-02-21
JP2015526464A (ja) 2015-09-10
CN104540502A (zh) 2015-04-22
US8475775B1 (en) 2013-07-02
JP6382817B2 (ja) 2018-08-29
RU2015103469A (ru) 2016-10-20
AU2013306281B2 (en) 2018-08-02
MX2015002340A (es) 2015-08-05
NZ704496A (en) 2017-01-27
BR112015003561A8 (pt) 2018-01-23
CO7350653A2 (es) 2015-08-10
WO2014031242A1 (en) 2014-02-27
KR20150045450A (ko) 2015-04-28
BR112015003561A2 (pt) 2017-07-04
EP2887928A4 (en) 2016-03-23
CL2015000434A1 (es) 2015-07-17
IN2015DN01524A (OSRAM) 2015-07-03
RU2687285C2 (ru) 2019-05-13
US20140057982A1 (en) 2014-02-27
IL236991B (en) 2019-03-31
EP2887928A1 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
JP6382817B2 (ja) レチノイドおよびその使用
KR101962658B1 (ko) 피부 상태를 치료하기 위한 조성물 및 방법
JP5732471B2 (ja) 溶媒混合物およびビタミンd誘導体から成る医薬品組成物または類似体
AU2024204696A1 (en) Treatment of cutaneous disorders
KR20040105706A (ko) 화학적 예방 활성을 나타내는 비스테로이드계 소염제를함유하는 국소 제형
CA2875052C (en) Method for treating skin inflammatory diseases
JP2013544857A (ja) 皮膚疾患の治療のための局所使用のための組成物
WO2018164662A1 (en) Resveratrol esters
US20250281493A1 (en) Methods for treating congenital epidermal hyperplasia and compositions for same
SG176097A1 (en) Topical retinoid solutions
EP2838508A1 (en) Formulations and methods for treatment of acne and inflammatory skin conditions
JP2647880B2 (ja) にきび及び皮膚病治療のための局所代替薬
CN101180028B (zh) 金刚烷基甲氧基二苯基丙烯酸用于治疗痤疮的用途
Connor et al. Epidermal Cell Growth in vivo
JP2006526662A (ja) 過増殖性細胞疾患を治療する方法
ITMI20121965A1 (it) Composizione topica per il rilascio transepidermico o transdermico di paracetamolo
WO2025222091A9 (en) Poly inflammatory kinase inhibitors and pharmaceutical compositions
RU2624238C2 (ru) Лечение себореи
Schmid et al. Permeation behavior of the NSAID ibuprofen from different poloxamer 407-based formulations through isolated human stratum corneum (Poster und Kurzvortrag). 17
WO2019070142A2 (en) TOPICAL LOTION FOR THE TREATMENT OF THE HAIR FALL (BIOHAIR®)
HK1117737B (en) Use of adamantyl methoxydi phenyl propenoic acid for the treatment of acne
ITCE20070006A1 (it) Nuova indicazione clinica per l'uso topico del misoprostolo: il prurito in campo dermatologico